Search

Displaying results 2981 - 2990 of 10000 in total
  1. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis. … LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

  2. Target

    Splicing factor, proline- and glutamine-rich

    go.drugbank.com/bio_entities/BE0008965
    TargetHumans

    Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune … The SFPQ-NONO-NR5A1 complex binds to the CYP17 promoter and regulates basal and cAMP-dependent transcriptional activity.

    Synonyms: DNA-binding p52/p100 complex, 100 kDa subunit
  3. Target

    Inter-alpha-trypsin inhibitor heavy chain H2

    go.drugbank.com/bio_entities/BE0009060
    TargetHumans

    May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are ...

    Synonyms: Inter-alpha-trypsin inhibitor complex component II
  4. Target

    Inter-alpha-trypsin inhibitor heavy chain H1

    go.drugbank.com/bio_entities/BE0009080
    TargetEnzymeHumans

    May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are ...

    Synonyms: Inter-alpha-trypsin inhibitor complex component III
  5. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    International brands: E-CaproMixtures: Relief and Nature Toothpast E Jasmine Mint
  6. Drug

    Acebutolol

    go.drugbank.com/drugs/DB01193
    ApprovedInvestigational

    A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.

    Synonyms: N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide
  7. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  8. Drug

    Phenoxymethylpenicillin

    go.drugbank.com/drugs/DB00417
    ApprovedInvestigationalVet approved

    An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms … Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms.

    International brands: Pen-V, Apo-Pen-VKProducts: Pen-VK, PEN-VI-K
  9. Target

    Proteasome subunit alpha type-6

    go.drugbank.com/bio_entities/BE0003915
    TargetHumans

    Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)

    Synonyms: Multicatalytic endopeptidase complex iota chain
  10. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including

    Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL